Sublingual absorption of micronized 17beta-estradiol

Area of Science:

• Endocrinology
• Pharmacology
• Women's Health

Background:

• Menopause is associated with decreased estrogen levels, leading to various symptoms.
• Micronized 17beta-estradiol (E2) is a form of estrogen used in hormone replacement therapy.
• Sublingual administration offers an alternative route for drug delivery.

Purpose of the Study:

• To evaluate the sublingual absorption, sustained effects, biological activity, and metabolism of micronized 17beta-estradiol (E2).
• To assess the impact of sublingual E2 on hormone levels in postmenopausal women.

Main Methods:

• 10 postmenopausal women participated in the study.
• Micronized E2 (0.5 mg) was administered either as a single sublingual dose or every other night.
• Serum E2, estrone (E1), FSH, and LH levels were measured over time.

Main Results:

• A single sublingual dose of E2 caused a rapid and significant increase in serum E2 and E1 levels within 1 hour.
• Serum FSH and LH levels decreased significantly within 6 hours post-dose.
• Alternate-day sublingual E2 administration maintained elevated estrogen levels above baseline for the study duration.

Conclusions:

• Sublingual administration of micronized E2 is an effective method for achieving sustained estrogen levels in postmenopausal women.
• This route of administration leads to significant suppression of FSH and LH.
• Sublingual E2 demonstrates favorable pharmacokinetic and pharmacodynamic properties for managing menopausal symptoms.